NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ABVX

Abivax ADR

Jul 03 • 02:20PM ET

7.96

Dollar change +0.20
Percentage change 2.58	%

Healthcare • Biotechnology • France • NASD

Peers: GILD VRTX AMGN REGN BIIB BMY MRNA PFE LLY NBIX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.02	Insider Own	12.35%	Shs Outstand	63.35M	Perf Week	10.86%
Market Cap	505.22M	Forward P/E	-	EPS next Y	-2.11	Insider Trans	0.00%	Shs Float	55.63M	Perf Month	2.84%
Enterprise Value	455.49M	PEG	-	EPS next Q	-0.92	Inst Own	39.28%	Short Float	2.27%	Perf Quarter	31.57%
Income	-190.65M	P/S	-	EPS this Y	-0.11%	Inst Trans	19.98%	Short Ratio	6.21	Perf Half Y	12.91%
Sales	0.00M	P/B	12.00	EPS next Y	32.59%	ROA	-66.45%	Short Interest	1.26M	Perf YTD	8.74%
Book/sh	0.66	P/C	3.38	EPS next 5Y	15.87%	ROE	-147.48%	52W High	14.16 -43.79%	Perf Year	-41.30%
Cash/sh	2.35	P/FCF	-	EPS past 3/5Y	-1.20% -1.44%	ROIC	-197.95%	52W Low	4.77 66.88%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.72% 6.91%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	18.47%	Oper. Margin	-	ATR (14)	0.50	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.82	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	65.79	Recom	1.17
Dividend Gr. 3/5Y	- -	Current Ratio	1.82	EPS Q/Q	24.42%	SMA20	10.82%	Beta	0.32	Target Price	32.57
Payout	-	Debt/Eq	2.37	Sales Q/Q	-	SMA50	17.35%	Rel Volume	1.84	Prev Close	7.76
Employees	69	LT Debt/Eq	1.29	Earnings	Jun 02 AMC	SMA200	2.85%	Avg Volume	203.70K	Price	7.96
IPO	Oct 20, 2023	Option/Short	No / Yes	EPS/Sales Surpr.	-16.05% 169.36%	Trades		Volume	374,623	Change	2.58%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-20-25	Initiated	Morgan Stanley	Equal-Weight	$12
Dec-04-24	Initiated	JMP Securities	Mkt Outperform	$33
Jul-29-24	Initiated	Laidlaw	Buy	$48
May-20-24	Initiated	BTIG Research	Buy	$43
Apr-29-24	Initiated	Piper Sandler	Overweight	$42
Apr-29-24	Initiated	Guggenheim	Buy	$50
Nov-14-23	Initiated	Morgan Stanley	Equal-Weight	$15
Nov-14-23	Initiated	Leerink Partners	Outperform	$20

Jun-11-25 04:00PM	Abivax Announces Results of its June 6, 2025 Annual General Meeting (GlobeNewswire) -5.72% -5.39%
Jun-02-25 04:00PM	Abivax Presents First Quarter 2025 Financial Results (GlobeNewswire) +5.48% +21.89%
Apr-29-25 04:05PM	Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis (GlobeNewswire)
Apr-22-25 04:05PM	Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones (GlobeNewswire)
04:00PM	Abivax Announces Appointment of Dominik H chli, MD to Board of Directors (GlobeNewswire)
04:00PM	Loading…
04:00PM	Abivax Announces Appointment of Dominik Hochli, MD to Board of Directors (GlobeNewswire)
Mar-27-25 07:20PM	ABIVAX: Undercovered, Late-Stage French Company With Upcoming Catalysts (SeekingAlpha) -5.72%
Mar-26-25 05:05PM	Abivax publishes financial reports with the French and U.S. securities regulatory agencies (GlobeNewswire)
Mar-24-25 03:30AM	Abivax Announces Full Year 2024 Financial Results (GlobeNewswire)
Feb-21-25 02:30AM	Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 (GlobeNewswire) +6.04%
Jan-28-25 02:30AM	Abivax Publishes 2025 Financial Calendar (GlobeNewswire)
Jan-23-25 04:05PM	Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress (GlobeNewswire)
Jan-09-25 11:35AM	Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment (GlobeNewswire)
Dec-23-24 04:05PM	Abivax Announces a Change to the Composition of its Board of Directors (GlobeNewswire)
Nov-19-24 04:30PM	Abivax Establishes an At-the-Market (ATM) Program on Nasdaq (GlobeNewswire)
04:01PM	Loading…
Nov-14-24 04:01PM	Abivax presents third quarter 2024 key financial information (GlobeNewswire)
Nov-13-24 04:01PM	Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax (GlobeNewswire)
Oct-07-24 04:01PM	Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation (GlobeNewswire)
Oct-03-24 04:01PM	Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease (GlobeNewswire)
02:31AM	Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance (GlobeNewswire)
Sep-26-24 02:30AM	Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 (GlobeNewswire)
Sep-25-24 04:01PM	Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model (GlobeNewswire)
Sep-09-24 04:01PM	Abivax presents first-half 2024 financial results (GlobeNewswire)
Aug-06-24 02:30AM	Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone (GlobeNewswire)
Jul-15-24 04:00PM	Abivax Provides Operational and Key Program Update (GlobeNewswire)
Jun-04-24 04:10PM	Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting (GlobeNewswire)
May-08-24 02:30AM	Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 (GlobeNewswire)
May-07-24 04:00PM	Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents (GlobeNewswire)
Apr-05-24 04:00PM	Abivax publishes financial reports with the French and U.S. securities regulatory agencies (GlobeNewswire)
Apr-02-24 02:30AM	Abivax reports 2023 financial results and operational update (GlobeNewswire)
02:50AM	Loading…
Feb-13-24 02:50AM	Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO) (ACCESSWIRE)
Feb-07-24 02:30AM	Abivax appoints Ana Sharma as Vice President, Global Head of Quality (GlobeNewswire)
Feb-02-24 02:30AM	Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease (GlobeNewswire)
Jan-24-24 02:30AM	Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 (GlobeNewswire)
Jan-22-24 02:30AM	Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months (GlobeNewswire)
Jan-04-24 02:30AM	Abivax 2024 Financial Communication Calendar (GlobeNewswire)
Nov-21-23 02:30AM	Abivax announces the resumption of its liquidity contract (GlobeNewswire)
Nov-14-23 08:00AM	Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Oct-24-23 04:15PM	Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market (ACCESSWIRE) +7.90%

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABVX

Abivax ADR

Upgrade your FINVIZ experience